A 13-page Quarterly Update is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases.
Snapshot
Bioxytran, Inc. (“Bioxytran” or “the Company”) is a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases.
Bioxytran’s glycovirology efforts, conducted through its subsidiary, Pharmalectin Inc., are focused on developing a novel technology platform—ProLectin—designed to reduce the viral load and modulate the immune system through galectin-3 inhibition. Galectin-3 inhibitors have the capability to bind with proteins on the surface of a virus, preventing the virus from attaching to and entering the cell. Using its ProLectin technology platform, Bioxytran is developing a group of therapeutic candidates that provide an end-to-end solution for COVID-19, including treatment for severe conditions derived from the disease. The Company’s lead candidate, ProLectin-M, is a chewable tablet for treating mild-to-moderate COVID-19 that binds with the spike proteins on the virus’ surface and acts as a cell-entry inhibitor.
With an initial focus on COVID-19, Bioxytran believes that its technology can be used to create therapeutics targeting a considerable number of viruses, as well as the potential creation of a single molecule designed to target multiple receptors responsible for various aspects of a disease. Bioxytran’s second technology platform—its hypoxia program—relies on the application of its proprietary co-polymer chemistry manufacturing process to enhance the hemoglobin molecule, creating an injectable intravenous drug that prevents necrosis by carrying oxygen to brain cells that have limited or blocked blood flow. Bioxytran’s lead candidate in this research area is BXT-25, an oxygen-carrying small molecule intended to treat hypoxic conditions in the brain resulting from stroke. BXT-25 development is on hold pending the raise of additional capital.
Key Points of Bioxytran, Inc.
- On November 16th, the Company announced positive topline safety and efficacy results of its randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered 8 times per day on an hourly basis. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value=.001) and something that has only ever been accomplished by one other drug in the past decade. The Company’s analysis also revealed an 88% response rate by day 3, which was statistically significant (p-value=.001).
- Bioxytran announced on December 8th that it had received an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to optimize dosage in COVID-19 patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.
- The Company announced that it had established an Indian subsidiary (Pharmalectin India Private Limited), with a purpose to launch commercial product sales of ProLectin-M should the company receive Central Drugs Standard Control Organization (CDSCO) approval. The Indian manufacturing plant is an FDA-approved facility that is capable of supporting the Indian market with a population of 1.4 billion people.
- Bioxytran has developed what it believes to be a potential cure for COVID. The Company believes that its drug can be used as a method of prophylaxis (a first line of defense against all mutation of coronaviruses) to prevent an individual from getting infected with the virus.
- The Company’s cash position as of September 30, 2022 was $374,190.
*******************************************
Visit our Corporate Profile and Investment Highlights pages
for the latest research on Bioxytran, Inc.
*******************************************